TRPV1 (previously known as VR1) is a non-selective ligand-gated ion channel and is a member of the transient receptor potential (TRP) superfamily. Caterina and colleagues 1 cloned TRPV1 from a rat dorsal root cDNA library encoding a protein of 838 amino acids with a molecular mass of 95 kDa. Cloning studies by other groups revealed close sequence homology across a range of species. [2] [3] [4] A series of related TRPV channels have been described which display differences in activation and are proposed to function in a range of sensory roles. 5 TRPV1 is relatively highly expressed in sensory neurones, with lower expression in brain, kidney, lung and spleen. 1 3 Capsaicin, the pungent vanilloid component in chilli peppers, is the classic agonist at TRPV1 on C-fibres and a small population of Ad-fibres. Depolarization of the sensory nerves involves an influx of sodium and calcium ions with the generated action potential perceived as pain. Paradoxically, sustained application of capsaicin induces analgesia, which is likely to result from a chemical denervation. 6 
D
9 -Tetrahydrocannabinol (THC), the major psychoactive compound from maurijuana (Cannabis sativa), binds to CB 1 located in mammalian brain. 7 There is much current interest and controversy regarding the use of cannabis and cannabinoids for the treatment of pain. [7] [8] [9] Identification of an endogenous ligand at TRPV1 is controversial. However, anandamide (AEA) has been proposed as an ideal candidate because of its structural similarity to capsaicin ( Fig. 1 ) and lipids are thought to regulate TRP channel function. 10 Moreover, this suggests some overlap between TRPV1 and CB 1 receptor systems. In addition, AEA was found to produce vasodilation in arterial preparations, although this action was only sensitive to the TRPV1 antagonist capsazepine and not to the CB 1 antagonist SR141716A. 11 Also, AEA activates TRPV1 in recombinant and endogenous systems, which reinforces the possibility that it functions as an endovanilloid. 12 TRPV1 can also be described as polymodal as it can be activated by noxious heat (>43 C), protons and various lipids including the endocannabinoid AEA. Activation of recombinant TRPV1 by capsaicin, acid, heat and AEA is blocked by the competitive antagonist capsazepine, 13 although there are marked differences in its antagonist potency against these different TRPV1 activators.
Mice lacking TRPV1 receptors displayed decreased capsaicin sensitivity and thermal hyperalgesia, implicating TRPV1 function in nociceptive processing and inflammation.
14 Capsaicin is used in the pain clinic as a topical cream for chronic pain of neuropathic or musculoskeletal origin. A recent review concluded that capsaicin had moderate to poor efficacy in treatment of moderate or severe chronic pain. Also, local adverse effects limited continual use of capsaicin for some patients. However, capsaicin is beneficial to patients who are unresponsive to, or intolerant of, other treatments. 15 Clearly, there is a need for non-pungent TRPV1 agonists and model systems in which to evaluate their activity. Measurements of intracellular Ca 2+ in cells expressing recombinant TRPV1 receptors is of value as the TRPV1 receptor is located on nociceptors whose activation produces a Ca 2+ -dependent release of excitatory transmitters. 16 Desensitization following capsaicin application is preceded by a rise in Ca 2+ ; 17 however, there was no capsaicin-mediated rise in Ca 2+ in cultured dorsal root ganglion (DRG) neurones from TRPV1 knockout animals and no paw licking/shaking behaviour was observed in these animals. 14 There have been few studies characterizing and comparing recombinant rat (r) and human (h) TRPV1 receptors. Therefore in this study we have made a detailed comparison of rat and human TRPV1 receptors heterologously expressed in human embryonic kidney (HEK293) cells (HEK293 rTRPV1 , HEK293 hTRPV1 ). As an index of receptor activation, we have measured intracellular Ca 2+ ([Ca 2+ ] i ) in Fura-2-loaded cells and examined the effects of a range of agonists and antagonists at the two most common experimental temperatures (22 and 37 C) to facilitate comparison with the literature. In addition, we have examined the effects of AEA (endocannabinoid) and THC (exocannabinoid) at both TRPV1 and CB 1 (endogenously expressed in rat cerebellum) to compare exo-and endocannabinoids and any dual activation of TRPV1 and CB 1 receptors. 
Materials and methods

Sources of materials
Drug stocks
For fluorimetry, 10 mM stocks of capsaicin and anandamide were prepared in DMSO and further diluted in Krebs-HEPES buffer for the former and a mix of Krebs-HEPES buffer and DMSO for the latter (owing to the high insolubility of anandamide) when required. A 10 mM stock of capsazepine was prepared in DMSO and further diluted in Krebs-HEPES buffer. A 10 mM stock of THC was prepared in ethanol and further diluted in ethanol on ice when required.
For the [ Solvent controls were used as appropriate. All stocks were stored at À20 C and dilutions of the stocks were prepared fresh on the day of an experiment.
Cell culture
HEK293 hTRPV1 and HEK293 rTRPV1 cells (passages [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] were maintained in minimum essential medium (MEM) supplemented with 10% fetal calf serum, L-glutamine 0.2 mM, fungizone 2.5 mg ml À1 , penicillin 100 IU ml
À1
and streptomycin 100 mg ml À1 at 37 C in 5% carbon dioxide-air mixture. Cells were passaged with trypsin-EDTA when required and used when confluent.
Fluorimetric measurement of intracellular free calcium [Ca
Cells were detached, and were washed twice with and suspended in Krebs-HEPES buffer of the following composition: NaCl 143 mM, glucose 11.7 mM, HEPES 10 mM, KCl 4.7 mM, KH 2 PO 4 1.2 mM, MgSO 4 1.2 mM and CaCl 2 2.6 mM. Suspensions were incubated with a final concentration of 5 mM Fura-2AM for 30 min at 37
C. The cells were resuspended again in Krebs-HEPES buffer and incubated for a further 20 min at room temperature in the dark to allow for dye de-esterification. The cells were then resuspended in Krebs-HEPES buffer and stored on ice until required.
Aliquots (1.8 ml) of warmed Krebs-HEPES buffer and 200 ml cells were pipetted into a quartz cuvette containing a small magnetic stirrer that was finally placed ino a PerkinElmer LS50B fluorimeter. The temperature of the cuvette was maintained by external water tubes connected to a water bath that was heated 2 C above the desired temperature to compensate for intermediate cooling. The temperature was confirmed using a thermocouple thermometer. The cells were allowed to warm to the required temperature for 2 min prior to the addition of different agonists at varying concentrations. The antagonist capsazepine was preincubated for 10 min prior to the addition of agonist. As this was a cuvette-based assay, single concentrations of agonists were used in different cuvettes, i.e. concentration response curves were not cumulative. Fluorescence emission was measured at 510 nm with excitation at 340 nm and 380 nm. [Ca 2+ ] i was estimated using built-in software (FLDM, Perkin-Elmer) and the Grynkiewicz equation. 18 R max and R min were obtained with Triton-X100 and EGTA respectively. The K d values for Fura-2 were 145 nM and 225 nM at 22 C and 37 C, respectively. 22 Then, 20 mg of membranes were incubated in 0.5 ml volumes of buffer containing Tris 50 mM, EGTA 0.2 mM, magnesium chloride 1 mM, sodium chloride 100 mM, bacitracin 0.15 mM, GDP 5 mM, [ 35 S]GTPgS $150 pM and different ligands at various concentrations. The reaction was incubated for 1 h at 30 C with gentle shaking and terminated by filtration through Whatman GF/B filters using a Brandel harvester. Non-specific binding was determined in the presence of GTPgS 10 mM.
Data analysis
Data are presented as mean (SEM) of n experiments or as single representative fluorimetric traces (from n experiments ] i ) and analysed using GRAPHPAD PRISM (V3.0) to derive potency pEC 50 (concentration producing 50% of the maximum response E max ) and efficacy E max . [ 35 S]GTPgS data were expressed as stimulation factor (ratio of agoniststimulated specific binding to basal specific binding) and analysed using GRAPHPAD PRISM (V3.0). Fits were 'sigmoid concentration response curves'. In capsazepine inhibition studies data were normalized to the maximum response produced by capsaicin alone and apparent pK B values (antagonist potency) were calculated using the Gaddum-Schild equation assuming a slope of unity:
Where appropriate, data were analysed using unpaired t-tests or analysis of variance (ANOVA) with the Bonferroni correction. Differences were considered significant when P<0.05. Comparison of capsaicin and the endocannabinoid anandamide at TRPV1 Figure 3 shows capsaicin concentration response curves in HEK293 hTRPV1 and HEK293 rTRPV1 cells at 22 and 37 C and the corresponding pEC 50 values are given in Table 1 . Generally, there was no difference in the potency, which ranged from 132 to 275 nM, between receptor species and temperatures. However, the potency of capsaicin in HEK293 rTRPV1 cells increased significantly at 37 C relative to 22 C (P=0.05). There was a temperature-dependent increase in E max at both receptor species. AEA also produced a concentration-dependent increase in [Ca 2+ ] i in HEK293 hTRPV1 and HEK293 rTRPV1 cells at 22 and 37 C ( Figure 3 and Table 1 ).
Results
Typical temporal profiles
Overall, EC 50 ranged from 1.5 to 4.8 mM. Similar to capsaicin, there was generally no difference in response to AEA. However, the efficacy at 37 C increased relative to that at 22 C at both receptors. At rat TRPV1 receptors (with lower expression), AEA acted as a partial agonist relative to capsaicin at both temperatures. The relative intrinsic activity values a of capsaicin relative to AEA at rTRPV1 were 0.36 and 0.29 at 22 C and 37 C, respectively, and at hTRPV1 were 0.96 and 0.75 at 22 C and 37 C, respectively.
Capsazepine antagonism
Capsazepine 30 mM competitively antagonized the capsaicin-mediated increase in [Ca 2+ ] i in HEK293 hTRPV1 and HEK293 rTRPV1 at 22 and 37 C ( Figure 4 and Table 2 ). Capsazepine was $6-fold more potent at hTRPV1 than at rTRPV1. pK B analysis with AEA as the agonist could not be performed because of its low potency and relative insolubility.
Effects of the exocannabinoid THC at hTRPV1
THC 100 mM (in 170 mM ethanol) produced a timedependent increase in [Ca 2+ ] i in HEK293 hTRPV1 at 37 C (Fig. 5A) . However, this could be mimicked by the addition Table 1 .
Lam et al.
of 170 mM ethanol alone and in a capsazepine (30 mM) sensitive manner (Fig. 5B) . The ethanol effect was probed further and appeared to be concentration dependent. However, the response failed to saturate despite using concentrations up to 1.5 M (Fig. 5C ).
[ (Fig. 6 ). The pEC 50 value of AEA at CB 1 is in agreement with that at hTRPV1 and rTRPV1 at 22 and 37 C (P>0.05).
Discussion
Capsaicin and anandamide TRPV1, a ligand-gated Ca 2+ -permeable ion channel, is involved in nociceptive signalling and this receptor is a therapeutic target in pain management. 23 Capsaicin and AEA are agonists at recombinant rat and human TRPV1 receptors 4 13 24 25 and native TRPV1 in sensory neurons. 1 26 The capsaicin response at recombinant rat and human TRPV1 receptors was examined at 22 and 37 C (two commonly used experimental temperatures) and there was a temperature-dependent increase in maximum response (with no major changes in potency). However, we have previously reported for recombinant HEK293 rTRPV1 cells that capsaicin potency decreased with increasing temperature, although in our original paper we went up to 50 C, a temperature that would activate TRPV1. 24 We have no explanation for this discrepancy. At rTRPV1 the pEC 50 value reported here of 6.56 for capsaicin (22 C) was 4 24 in transfected HEK293 cells. However, the pEC 50 values at 37 C were in good agreement. 24 At hTRPV1, our pEC 50 values for capsaicin were 6.88 and 6.77 at 22 C and 37 C, respectively, and these were in reasonable agreement with those determined from FLIPR-based calcium assays in HEK293 hTRPV1 at 25 C. 13 25 Species differences for capsaicin have not been reported in other studies. 4 13 25 At the higher capsaicin concentrations (100 mM) there was an apparent decline in Ca 2+ responses which we feel may result from an acute desensitization.
The endocannabinoid AEA activates not only the CB 1 receptor 27 but also TRPV1. 28 AEA response at hTRPV1 at 22 C (pEC 50 =5.82) is consistent with reported values of 5.6, 13 5.95 25 and 5.69. 24 No difference in potency was observed for the AEA response at hTRPV1 or rTRPV1 with increasing temperature but there was an increase in maximum response, consistent with changes observed for capsaicin. Reports differ in classifying AEA as either a partial 28 or full agonist at recombinant TRPV1, 25 and this may be due to species or expression differences. We have shown that AEA is a partial agonist in rat, whilst in human a full agonist profile is observed. As more receptors are present in cells expressing the human clone, we suspect that higher expression coupled with the possible introduction of a receptor reserve increases relative intrinsic activity.
Capsazepine
Capsazepine is a competitive antagonist at TRPV1. 29 We have clearly shown competitive antagonism at both rTRPV1 and hTRPV1 at 22 and 37 C with this molecule. Capsazepine potency was not temperature-dependent at TRPV1, as confirmed by others, 30 but there was an $6-fold increase in capsazepine potency for hTRPV1 compared with rTRPV1. This difference is consistent with that reported by McIntyre and colleagues. 31 pK B values for this antagonist have proved highly variable; for example, in FLIPR-based assays, this varied from 6.58 to 7.31 in HEK293 hTRPV1 cells 13 25 and to 7.52 in HEK293 rTRPV1 . 4 Other reports include values of 6.04 in guinea-pig trachea, 5.12 in guinea-pig bronchi (sensory neurones) and 6.65 at rTRPV1 transfected Chinese hamster ovary (CHO) cells. [31] [32] [33] The reason for these differences is unclear.
Investigation of exocannabinoid activity at TRPV1
The exocannabinoid THC activates CB 1 receptors; however, activity at TRPV1 has not been extensively examined. We have attempted to determine whether THC was able to activate TRPV1 in a similar fashion to that of the endocannabinoid AEA. THC produced elevated [Ca 2+ ] i levels but subsequent investigations with an ethanol control attributed this effect to ethanol only. These results are supported by ethanol activity at TRPV1 reported by Trevisani and colleagues. 34 Capsaicin, AEA, protons and heat can potentiate the modulation of TRPV1 activity by ethanol. Also, the threshold for heat activation of TRPV1 dropped from 42 to 34 C. Ethanol was found to increase the potency and efficacy of capsaicin and caused the release of substance P from central and peripheral terminals of capsaicinsensitive nociceptors in C-and Ad-fibres. Release of substance P is related to the pain sensation, and ethanol can lower the threshold of TRPV1 to body temperature; thus the data provided an explanation for the burning pain sensed by patients with oesophagitis after consuming alcoholic beverages. 34 These data indicate that endo-rather than exocannabinoids are TRPV1 activators.
The [ 35 S]GTPgS binding assay was employed to act as a positive control for THC activity and to allow a comparison of AEA potency at CB 1 and TRPV1 to be made. Both AEA and THC activated the CB 1 receptor. AEA displayed a lower potency than a previously reported pEC 50 value of 6.56, while THC was consistent with the literature. 35 Our data demonstrated that THC was a partial agonist relative to AEA. As expected, capsaicin had no effect at the CB 1 receptor.
Speculation exists over the possibility that AEA and other similar unidentified lipid compounds are endogenous ligands at TRPV1. We have clearly demonstrated that AEA is active at both TRPV1 and CB 1 . It has been known for some time that TRPV1 receptors mediate the vasodilation produced in response to AEA. 28 In summary, capsaicin activates TRPV1, THC activates CB 1 and AEA activates both receptors. Therefore it is tempting to suggest that CB 1 and TRPV1 may be metabotrophic and ionotrophic members of a family of endocannabinoid receptors. Effects of exo-and endocannabinoids
